Evidence map›Paper›PMID 42812315›Full record

ArticleFrontiers in public health2026

Serological evidence uncovers undocumented mpox exposure in febrile patients in Nigeria.

Jolly A Adole, Sandra E Omaga, Precious E Oyamendan, Utibe M Dennis, Oluremi I Ajayi, Amoge C Ogu, Ifeoluwa O Bejide, Johnson Okolie, Philomena Eromon, Christian T Happi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jolly A AdoleInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Sandra E OmagaInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Precious E OyamendanInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Utibe M DennisInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Oluremi I AjayiInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Amoge C OguInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Ifeoluwa O BejideInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Johnson OkolieInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Philomena EromonInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Christian T HappiInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.
Chinedu A UgwuInstitute of Genomics and Global Health (IGH), Redeemer's University, Ede, Nigeria.

Funding

Bill & Melinda Gates Foundation INV-036304
6 · The paper itself

Abstract

Introduction: The monkeypox virus (MPXV) has become a global health threat, with rising cases reported globally. Since its re-emergence in 2017, Nigeria has experienced a sustained outbreak, underscoring the critical need for robust surveillance mechanisms to identify transmission dynamics. Despite this urgency, data regarding MPXV seroprevalence among patients seeking medical care in Nigeria remains scarce. MPXV may be underreported because its clinical symptoms overlap with those of other common causes of fever. Methods: We assess MPXV seroprevalence among febrile patients across multiple Nigerian healthcare facilities using A35R and A29L antigens in a Luminex bead-based immunoassay. The study enrolled 245 febrile individuals in Ondo, Benue, Plateau, and Osun States from June 2023 to July 2024. Plasma samples were analyzed for antibodies targeting MPXV A35R and A29L antigens. A manual-based 3-standard-deviation threshold method and an R-based SeroNIST analytical framework were used. Statistical analyses assessed assay reliability and identified potential risk factors associated with MPXV exposure. Results and discussion: Both antigens showed comparable exposure patterns (

Indexed as

FeverMonkeypox virusMpox, MonkeypoxAdolescentAdultAgedAntibodies, ViralFemaleHumansMaleMiddle AgedNigeriaRisk FactorsSeroepidemiologic StudiesYoung AdultAntibodies, Viralfebrile patientshealthcare settingLuminex immunoassaymonkeypox virusNigeriapublic healthseroepidemiology

Identifiers

PMID42812315
PMCPMC13619595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.